Resources

In this webinar, researchers from Burkina Faso and Mozambique shared learnings on how country-tailored interventions have helped increase the uptake of the malaria vaccine.As part of Gavi’s Malaria Vaccine Learning Agenda, experts presented findings and lessons learned from the rollout of malaria vaccines in Mozambique and Burkina Faso, sharing strategies to increase uptake through routine immunization platforms. This was the first in a quarterly series this year on learnings from malaria vaccine rollout in Africa.The session was co-moderated by Eleonora Genovese, Senior Programme Manager, Vaccine Programmes, Gavi, the Vaccine Alliance, and Saira Nawaz, Project Director, Primary Health Care, PATH. Featured speakers included Dr. Ali Sie, Centre de Recherche en Santé de Nouna (CRSN), Burkina Faso, and Daan Velthausz, Director, Maraxis BV, Mozambique.

This brief outlines the current state of health research and development (R&D) financing in Africa and underscores the importance of sustained, country-led investment amid declining global funding. Following a temporary surge during the COVID-19 pandemic, global health R&D financing has contracted significantly. In this context, the analysis frames domestic investment and governance of health R&D as contributors to health security and sovereignty, enabling countries to set national and regional priorities. Where predictable, country-led funding is absent, R&D pathways become fragmented, slowing product development and delaying patient access to lifesaving innovations.Against this backdrop, the brief highlights the need for more coordinated and resilient approaches to financing health R&D in Africa. Drawing on discussions co-hosted by PATH and Impact Global Health, it points to strong evidence that investment in health R&D generates substantial societal and economic returns, strengthens pandemic preparedness, and supports the development of local manufacturing capacity. The recommended actions collectively aim at building sustainable, Africa-led health R&D ecosystems.

Medical oxygen is a critical component of a well-functioning health system, yet only 30 percent of patients in low- and middle-income countries (LMICs) who need oxygen receive it. Key access barriers that drive this coverage gap include (1) supply and delivery challenges, such as limited production capacity, costly installation and maintenance requirements, and inadequate procurement and supply systems; (2) affordability, such as high cost of products and lack of local manufacturers; and (3) demand and adoption barriers, such as limited sustainable funding and limited guidelines.This fact sheet offers an overview of the INNOVATE project, which aims to address critical barriers to oxygen access. PATH, through a consortium of partners, will catalyze promising oxygen production and piping technologies, along with innovative operation and maintenance business models, to expand equitable access. By strengthening production and delivery capacity in health facilities and improving efficiency across the oxygen value chain, INNOVATE aims to accelerate the adoption of more cost-effective and sustainable solutions.

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in young children. Two preventive interventions for RSV—a maternal vaccine and long-acting monoclonal antibodies (mAbs) delivered to infants—are recommended by the World Health Organization. When countries consider introducing new vaccines, immunization program cost and affordability are key questions.To address some of these questions, the University Medical Centre Utrecht and PATH conducted studies as part of a multi-country collaboration called the RSV GOLD III-Health Economics Study to evaluate the economic burden of RSV disease (or cost of illness) and the impact and cost-effectiveness of RSV prevention (e.g., via maternal immunization or long-acting monoclonal antibodies) in Gavi, the Vaccine Alliance-eligible countries. The estimates will help inform policy decisions in low- and middle-income countries where maternal immunization-preventable diseases often hit hardest.Find here links to the peer-reviewed journal articles and select fact sheets summarizing the research. [Note: Some publications and fact sheets are forthcoming.]

This document highlights the health impact of a variety of medical devices and health technologies in use around the world, such as SoloShot syringes, HEATmarker Vaccine Vial Monitors, Nifty Feeding Cups, Uniject injection systems, and safe water devices. Including innovations that have been produced at a scale of million and billions of units as well as more recent product introductions addressing critical global health needs are featured.